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Protease Inhibitors: A New Weapon and a New
Strategy Against HIV

K e n n e t h D. Phillips, P h D , RN

Until recently, reverse transcriptase inhibitors
have been the mainstay for treating HIV
infection. Now, three protease inhibitors have
been approved. Early evidence suggests that
triple therapy delays the progression of HIV
infection. An understanding of these new drugs
and treatment strategies is imperative for
clinicians. This article (1) reviews HIV's
structure and replication process, (2) discusses
currently approved reverse transcriptase and
protease inhibitors, (3) describes the
antiretroviral drugs" modes of action, (4)

Kenneth D. Phillips, PhD, RN, is Assistant Professor,
University of South Carolina, Columbia, SC.
A decade and a half after acquired immunodeficiency
syndrome (AIDS) was first identified, this life-threatening illness continues to elude a cure. Until recently,
reverse transcriptase inhibitors have been the mainstay
for treating HIV infection (Fischl et al., 1987; Weber, 1993;
Yarchoan et al., 1986; Yarchoan et al., 1989). In 1995, a
new classification of drugs, protease inhibitors, was
added to the armamentarium for treating HIV infection.
Although the data are limited, early evidence suggests
that a combination of reverse transcriptase inhibitors and
protease inhibitors delays the progression of HIV disease
and prolongs the lives of H1V- infected people (Collier et
al., 1996). Only one brief report regarding the use of protease inhibitors in combination therapy to treat HIV
infection was found in the nursing literature (New Wave,
1996). The purpose of this paper is to review HIV's replication process, discuss the different classifications of
antiretroviral agents, describe anfiretroviral drugs' mode
of action, and describe nursing implications for monitoring dients on these antiretroviral drugs.

discusses important nursing implications for
monitoring clients on these drugs, and (5)
presents current scientific evidence regarding the

Replication of the Human Immunodeficiency Virus

In order to understand how antiviral drugs work in
combating HIV, it is important to understand the structure and life cycle of the HW.

effectiveness of combination therapy strategies.

Key words: Antiretroviral therapy, HIV/AIDS,
protease inhibitors, reverse transcriptase
inhibitors
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Structure of the H u m a n Immunodeficiency Virus
HIV is the retrovirus responsible for AIDS (Barr6Sinoussi et al., 1983; Gallo & Wong-Staal, 1985;
Montagnier, 1985). Retroviruses contain their genetic
material on two single strands of ribonucleic acid (RNA)
rather than deoxyribonucleic acid (DNA). HIV consists
of an envelope and a core (Figure 1). The outer envelope
contains two important glycoproteins, gp120 and gp41.
Glycoprotein 120 enables HIV to bind to T helper cells
and other host cells that have a CD4+ receptor site on
57
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Figure 1. Structure of the Human Immunodeficiency Virus

Table 1. Components of the Human Immunodeficiency Virus
Location

9gp120

Coat glycoprotein Allows the HIV to bind
to CD4+ receptor sites
such as T helper cells.
Coat glycoprotein Allows the HIV envelope to fuse with the
plasma membrane of a
cell bearing a CD4+
receptor site.
Coat protein
Becomes part of the
outer coat of the new
HIM.
Core protein
Forms the core capsid,
which surrounds the
viral RNA and enzymes.
Core protein
Becomes part of the
nucleocapsid.
Core protein
Becomes part of the
nucleocapsid.
Core enzyme
Converts viral RNA to a
single strand of viral
DNA. The strand of
viral RNA and the
newly formed viral
DNA remain attached.
Core enzyme
Degrades the RNA template from the DNA,
leaving a single strand
of DNA.
Core enzyme
Makes an exact copy of
the single strand of
DNA and causes the
two strands of viral
DNA to join.
Core enzyme
Inserts the newly
formed double strand of
viral DNA into the DNA
of the host cell.
Core enzyme
Cleaves the proteins of
noninfectious, immature
virions, thus making
them infectious.

9 gp 41

9 p17
Figure by Tammy Simpson, University of South Carolina,
College of Nursing. Used with permission.

their cell membranes, and gp41 enables the viral envelope to fuse with the host cell membrane. The envelope
is lined with a viral protein, p17.
The core is surrounded b y a membrane that is made
u p of three proteins, p24, p6, and p7. The core contains
two strands of viral RNA and e n z y m e s - - r e v e r s e transcriptase, RNAse, polymerase, integrase, and protease
(Fauci, 1993; Gallo, 1987,1988; Greene, 1993; Haase, 1990).
Table I summarizes the virus' main components.
Life-Cycle of the H u m a n I m m u n o d e f i c i e n c y Virus

Figure 2 represents HIV's replication process. The
Roman numerals refer to the stages in HIV's replication
process. HIV replication takes place inside host cells bearing a CD4+ marker. A brief s u m m a r y of the stages of
H1V replication is presented to illustrate the point in the
life cycle of HIV that antiretroviral drugs work.

9p24

9 p6
9 p7
9 Reverse
transcriptase

9 RNAse

9 Polymerase

9 Integrase

9 Stage I. Glycoprotein 120 binds to the CD4+ protein on host cells.
9 Stage II. Glycoprotein 41 facilitates fusion of the
viral coat with the CD4+ cell membrane.
9 Stage III. Once inside the cell, the virus undergoes
an uncoating process and releases two single strands
of RNA into the cytoplasm of the CD4+ cell.
58

Function

Protein Coded

9 Protease

Adapted from Gallo, 1987,1988;Greene, 1993; Haase, 1990
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Figure 2. Life Cycle of the Human Immunodeficiency Virus
~,&A

gp41
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Figure by Tammy Simpson, University of South Carolina, College of Nursing. Used with permission.

9 Stage IV. A single strand of DNA is copied from
the RNA by the e n z y m e reverse transcriptase.
Reverse transcriptase contains two other enzymes:
RNAse and polymerase. RNAse is necessary to
remove the RNA from the DNA copy. Then, polymerase makes another exact copy of the viral DNA
and causes the two strands of DNA to join.
9 Stage V. The newly formed double strand of viral
DNA moves into the nucleus of the host cell,
where it is incorporated into the DNA of the host
cell by the enzyme integrase. The host cell begins
to make messenger RNA (mRNA). Then, mRNA
moves from the host cell nucleus to the ribosomes,
where it guides the production of viral proteins.
Transfer RNA (tRNA) carries amino acids from the
host cell cytoplasm to the ribosomes.
9 Stage VI. In the ribosomes, the amino acids are
assembled into large, inactive precursor proteins.
JANAC Vol.7, No. 5, September-October,1996

9 Stage VII. During this stage, immature virions are
released from the host cell through the process of
budding. These virions, which are noninfectious,
contain large precursor proteins that must be broken into smaller glycoproteins, proteins, and
enzymes before they become infectious.
9 Stage VIII. By the action of protease, these large
precursor proteins are split into a variety of smaller
glycoproteins, proteins, and e n z y m e s that are
essential for the virus to become a mature, infectious retrovirus.
There are several points in the life cycle of HIV where
a great deal of research has been directed at finding drug
therapies for HIV infection. The research has been
directed at preventing the: (1) binding of gp120 to the
CD4+ receptor sites, (2) fusion of the viral coat with the
cell membrane of the CD4+ receptor site, (3) uncoating of
the virus once inside the host cell, (4) synthesis of viral
59
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DNA from viral RNA by the action af reverse transcriptase, (5) degradation of viral RNA leaving it attached to
the newly formed strand of viral DNA, (6) insertion of
viral DNA into the host cell DNA by the integrase, (7)
protein synthesis in the rough endoplasmic reticulum of
the host cell, (8) budding, and (9) maturation of the
newly formed HIV by the action of protease (Johnston &
Hoth, 1993; Weber, 1993). Presently, the greatest success
in treating HW infection has been the use of reverse transcriptase inhibitors and protease inhibitors. Reverse transcriptase inhibitors work in Stage Ill by preventing transcription of viral R N A into viral DNA. Protease
inhibitors work in Stage VIII by preventing the cleavage
of precursor proteins into mature viral proteins.

Classifications of Antiretroviral Drugs
Reverse Transcriptase Inhibitors
Reverse transcriptase inhibitors comprise the first major
effective classification of antiretroviral drugs. Reverse transcriptase is an enzyme found in retroviruses that is necessary for their replication. The reverse transcriptase
inhibitors have shown effectiveness in preventing infection
of uninfected CD4+ cells (Fischl et al., 1987; Lambert et al.,
1990; Merigan et al., 1989; Yarchoan et al., 1989). They do
not block viral production by CD4+ cells that are chronically infected (Ashorn et al., 1990; Dreyer et al., 1989;
Kempf et al., 1990; McQuade et al., 1990; Meek et al., 1990;
Reedijk et al., 1995; Rich et al., 1990; Roberts et al., 1990).
Nucleoside analogues, such as AZT, are substituted
for natural substrates used to manufacture viral DNA.
The growing chains of viral DNA are prematurely terminated, thus preventing viral replication. Since HIV
mutates so rapidly (Martin, Redshaw, & Thomas, 1995),
resistance of HW to reverse transcriptase inhibitors and
other antiretroviral drugs frequently occurs early in the
course of t h e r a p y and h i n d e r s their effectiveness
(Boucher et al., 1992; Fitzgibbon et al., 1992; Larder,
Darby, & Richman, 1989; Reichman et al., 1993). This
problem can be reduced by using drug combinations.
For example, lamivudine, which is not effective when
60

used alone, slows development of resistance to zidovudine (Eron et al., 1995). Clients taking zidovudine plus
larnivudine showed significant improvements in CD4+
counts and viral load (Eron et al.). Table 2 summarizes
the nucleoside analogue reverse transcriptase inhibitors.

Protease Inhibitors
Proteases are enzymes that split the peptide bonds of
larger proteins into smaller proteins (Roose & Van
Noorden, 1995). HIV protease helps HIV mature (Kohl et
al., 1988; Peng, Ho, Chang, & Chang, 1989; Tang, Lin,
Hartsuck, & Lin, 1992). HIV protease is part of the precursor protein gp160 (Buegelski et al., 1994). HIV protease
autocleaves itself from the precursor protein gp160
(Buegelski, Kirsh, & Hart, 1994). Following autodeavage,
gpl60 is cleaved into the two glycoproteins of the viral coat
(Decroly et al., 1994). Then, HIV protease promotes maturation of HIV by splitt~g retroviral precursor polyproteins
into structurally essential glycoproteins and proteins
(Krausslich & Wimmer, 1988; Robins & Plattner, 1993;
T~sdale et al., 1995). Thus, HIV protease allows immature,
noninfectious virions to become mature, infectious virions.
Glycoprotein 160 is a polyprotein precursor that is
encoded by the gag- pol region of the HIV genome. H1V
protease splits gp160 into gp120 and gp41 (Decroly et al.,
1994). By chopping gp160 into its component parts, I-tW
protease promotes binding (gp120) of the virus to the
CD4+ receptor site and fusion (gp41) of the viral coat
with the CD4+ cell membrane. There are eight possible
cleavage sites on gp160. Nine m a t u r e proteins are
formed by the action of protease: (1) p17, (2) p24, (3) an
unknown protein, (4) p7, (5) p6, (6) protease, (7) reverse
transcriptase, (8) RNAse, and (9) integrase (Buegeiski et
al., 1994; Debouck et al., 1987; Gelderblom et al., 1990).
The proteins of HIV are summarized in Table 1.
Protease inhibitors prevent maturation of newly
formed virions by preventing the cleavage of HIV's
polyproteins (Ashore et al., 1990; Kohl et al., 1988; Loeb,
Hutchinson, Edgell, Farmerie, & Swanstrom, 1989; Tang
et al., 1992). Thus, protease inhibitors prevent immature,
noninfectious viruses from becoming mature, infectious
JANAC VoL 7, No. 5, September-October, 1996

Table 2. Reverse Transcriptase Inhibitors
Reverse Transcriptase Inhibitor

9 Zidovudine
(azidothymidine; AZT; ZDV)

9 Didanosine
(dideoxyinosine; ddI)

Adult Dose

200 mg orally q8h

Body weight > 132 lbs: 200 mg
orally q12h

Adverse Effects

Nursing Implications

Anemia
Granulocytopenia
Myopathy
Myositis

Monitor the client's complete
blood count.

Pancreatitis
Peripheral neuropathy
Hepatotoxicity

Since ddI is degraded in acid,
tablets must be crushed,
chewed, or dispersed in water
to release the buffer or given
with a buffered powder.

Body weight < 132 lbs: 125 mg
orally q12h

Instruct client to report muscle
pain and fatigue.

Inform dient to report abdominal pain, nausea, and vomiting.
9 Zalcitabine
(dideoxycytidine; ddC)

9 Stavudine (D4T)

0.75 mg orally q8h

Body weight > 132 lbs: 40 mg
orally q12h
Body weight < 132 lbs: 30 mg
orally q12h

9 Lamivudine (3TC)

150 mg orally ql2h

Pancreatitis
Peripheral neuropathy
Mouth ulcers
Esophageal ulcers
Cardiomyopathy
Anaphylaxis

Inform client to report abdominal pain, nausea, and vomiting.

Peripheral neuropathy
Neutropenia
Hepatotoxicity
Anemia

Instruct client to monitor for
signs of peripheral neuropathy.

Pancrealitis
Peripheral neuropathy
Headache
Myalgia

Instruct client to monitor for
signs of peripheral neuropathy.

Observe for indication of neutropenia.
May be administered with or
without food.
Inform client to report abdominal pain, nausea, and vomiting.
Instruct client to monitor for
signs of peripheral neuropathy.

Adapted from Olin, B. (1996). Facts and comparisons. St. Louis: Lippincott.

o n e s (Debouck et al., 1987; Gottlinger, Sodroski, &
Haseltine, 1989; Kohl et al., 1988; Tang et al., 1992). Many
antiretrovirally active protease inhibitors have been
developed (Buegelski et al., 1994; Tk~ctaleet al., 1995). The
three protease inhibitors (saquinavir, ritonavir, and indiJANAC Vol. 7, No. 5, September-Octobe~ 1996

navir) that have been approved by the Food and Drug
Administration (FDA) are summarized in Table 3.
S a q u i n a v i r . Saquinavir has been associated with
significant increases in CD4+ cell counts and few side
effects (Kitchen, Stewart, Bragman, & Weber, 1995). It
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Table 3. Protease Inhibitors
Protease Inhibitor

9 Saquinavir

Adult Dose

600 mg orally q8h

Adverse Effects

Diarrhea
Abdominal discomfort
Nausea
Photosensitivity

Nursing Implications

Instruct client to take with a
meal to increase absorption.
Grapefruit juice may increase
bioavaflability.
Instruct client to avoid prolonged exposure to direct sunlight until sensitivity to sunlight is known.

9 Ritonavir

600 mg orally q12h

Diarrhea
Nausea

Instruct client to take with
food.
Observe for elevations in
serum triglycerides, AST, ALT,
GGT, CPK, and uric acid.
Avoid coadministration of
nonsedating antihistamines,
sedative hypnotics, or antiarrhythmics (may be life- threatening).

9 Indinavir

800 mg orally q8h

Kidney stones
Hyperbilirubinemia

Instruct client not to take with
meals; however, if gastric distress occurs, take with a light
snack.
If didanosine is also prescribed, instruct client to take
the two drugs one hour apart.
Instruct client to increase oral
fluid intake.

Adapted from Olin, B. (1996). Facts and comparisons. St. Louis: Lippincott.

is u s u a l l y u s e d in c o m b i n a t i o n w i t h either A Z T or a
nuceloside analog (Davey, Goldschmidt, & Sande,
1996). S a q u i n a v i r is m o r e e f f e c t i v e in c o m b i n a t i o n
w i t h A Z T w h e n the client has not t a k e n A Z T previously. Since A Z T has b e e n w i d e l y p r e s c r i b e d in the
62

HIV- infected cohort, s o m e clinicians believe it m a y be
m o s t beneficial to combine saquinavir with either zalcitabine (ddC) or didanosine (ddI) (Davey et al., 1996).
Ritonavir. Ritonavir has been associated with signific a n t l y i n c r e a s e d C D 4 + c o u n t s ( D a n n e r et al., 1995;
JANAC
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Kelleher, Carr, Zaunders, & Cooper, 1996; Markowitz et
al., 1995), increased CD8+ counts (Kelleher et al.),
increased responsiveness to new antigens as measured by
phytohemagglutinin antigen [PHA] mitogen blastogenesis (KeUeher et al.), increased responsiveness to previously
encountered antigens (Kelleher et al.), and decreased viral
load (Danner et al.; Kelleher et al.; Markowitz et al.).
Following treatment with ritonavir, significant decreases
in CD4+ cells bearing a CD38 receptor site following treatment with fitonavir have been observed (Kelleher et al.);
this may be a very important finding, since an increase in
these cells is associated with disease progression (Giorgi et
al., 1994; Levacher et al., 1992).
Indinavir. In clinical trials, dramatic reductions in
viral load and improvements in CD4+ cell counts have
been reported in clients receiving indinavir. In fact, used
in combination with AZT and 3TC, viral loads have been
reduced to undetectable levels (Davey et al., 1996).

Triple Therapy: A New Strategy
Protease inhibitors have shown effectiveness when
used as a monotherapy (Danner et al., 1995; Kelleher et
al., 1996; Markowitz et al., 1995; Massari et al., 1996).
However, synergistic effects have been demonstrated
when reverse transcriptase inhibitors and the protease
inhibitors are combined (Collier et al., 1996; Kageyama et
al., 1992). The term synergy identifies the concept that the
beneficial effects of two or more drugs are greater when
the drugs are combined than would be expected if either
of the drugs was used alone. Synergistic effects have been
noted when certain reverse transcriptase inhibitors are
combined: (1) zidovudine [AZT] and lamivudine [3TC],
(2) zidovudine [AZT] and didanosine [dbl.], and (3)
zidovudine [AZT] and zalcitabine [ddC] (Merigan, 1995).
HIV's ability to develop resistance to drugs is a major
obstacle to effective treatment (Richman, 1993). The term
resistance refers to the concept that a previously effective
anfiretroviral drug becomes ineffective due to viral mutations. Viral mutations and subsequent resistance may be
slowed by using a combination of drugs (Vella et al.,
1995). For instance, resistance of HIV to zidovudine may
JANAC
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be delayed by combining zidovudine with a protease
inhibitor (Schapiro, Winters, & Merigan, 1995) or lamivudine (Davey et al., 1996). In cross-resistance, development
of resistance to one drug results in the development of
resistance to other drugs of the same classification or
other classifications. Cross-resistance is extremely problematic in HIV infection. Resistance to one protease
inhibitor may result in cross-resistance to other anfiretroviral drugs, in particular other protease inhibitors (Chen
et al., 1995; Condra et al., 1995). A mutation of only one
genetic sequence results in cross- resistance to stavudine
[d4T], didanosine [ddI], and dideoxycytidine [ddC]
(Merigan, 1995). The term resistance- reversal connotes the
concept that the d e v e l o p m e n t of resistance to one
antiretroviral drug undoes the resistance that has developed to another drug. An example of this is the phenotypic resistance-reversal noted in the coadministration of
z i d o v u d i n e and l a m i v u d i n e (Boucher et al., 1993;
Merigan; Staszewski, 1995).

Saquinavir, plus zidovudine, plus dideoxycytidine.
Phase II clinical trials indicate that combinations of
saquinavir (SQV), zidovudine (ZDV), and dideoxycytidine (ddC) synergistically decrease H1V replication. In a
study conducted by Collier et al. (1996), three treatment
regimens were used: (1) saquinavir (SQV), plus zidovudine (ZDV), plus dideoxycytidine (ddC); (2) zidovudine
(ZDV) plus dideoxycytidine (ddC); and (3) zidovudine
(ZDV) plus saquinavir (SQV). Patients receiving a combination of saquinavir (SQV), plus zidovudine (ZDV),
plus dideoxycytidine (ddC) demonstrated the greatest
increase in CD4+ counts and the greatest decrease in
viral load (Collier et al.).
Ritonavir, plus zidovudine, plus zalcitabine. The
effects of a six-month regimen of ritonavir, plus zidovudine, plus zalcitabine were studied in a group of 21
patients (Abramowicz, 1996). Viral load decreased to
undetectable levels in 5 of the 21 participants (Third
Conference on Human Retroviruses and Opportunistic
Infections, 1996) as reported in The Medical Letter on
Drugs and Therapeutics.
Indinavir, plus zidovudine, plus lamivudine. HIV
viral load decreased to undetectable levels over a four
63
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m o n t h treatment period in 20 of 22 clients taking
zidovudine (AZT), plus lamivudine (3TC), plus indinavir. The participants in this study had an average
CD4+ cell count of 1 7 5 / m m 3 (Third Conference on
H u m a n Retroviruses and Opportunistic Infections,
1996) as reported in The Medical Letter on Drugs and
Therapeutics (Abramowicz, 1996). In a separate study, a
s i x - m o n t h c o u r s e of indinavir, z i d o v u d i n e , a n d
lamivudine lowered HIV viral load to undetectable
levels in 11 of 19 patients. The 'participants were previously untreated and had an average CD4+ lymphocyte
count of 150 cells/mm 3 (Third Conference on Human
Retroviruses and Opportunistic Infections, 1996) as
r e p o r t e d in The Medical Letter on Drugs and
Therapeutics.

Nursing Implications
Nurses use a holistic approach in the prescription and
administration of medications. Administering antiretroviral drugs requires special attention to all stages of the
nursing process.

Assessment
A complete assessment should be performed prior
to prescribing or administering any medication. When
administering antiretroviral drugs, nurses need to be
especially careful to determine the patient's allergies
to medications (name of medication and type of reaction) and assess past opportunistic infections and
malignancies.
Nucleoside analogues. Data from a complete blood
count, lymphocyte subset enumeration, and a chemical
profile should be available prior to administering a
nucleoside analogue. Six assessments must be performed before administering a nucleoside analogue:
First, ensure that the patient does not have anemia
( h e m o g l o b i n < 9.5 g / d l ) or g r a n u l o c y t o p e n i a (<
1000/mm3). If either is present, special precautions are
needed when administering zidovudine. Second, check
for elevated serum creatinine, which could make the
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patient more prone to d r u g toxicity. Third, assess
patients for a history of pancreatitis, symptoms of pancreatitis (i.e., abdominal pain, nausea, and vomiting),
risk factors for pancreatitis (i.e., cholelithiasis and
ethanol abuse), and elevations in either serum amylase
or s e r u m lipase, which m a y indicate pancreatitis.
Pancreatitis is a potentially lethal side effect of nucleoside analogues. Fourth, assess for early signs of peripheral neuropathy (i.e., intermittent numbness, tingling,
or pain in hands or feet). Fifth, perform a complete
nutritional assessment (i.e., height, weight, serum albumin, serum transferrin, serum prealbumin, and a 24hour diet recall). Sixth, if the client is female, assess her
pregnancy status. Zidovudine has been shown to be
effective in preventing the vertical transmission of HIV
from the mother to the fetus without harming the fetus
when administered after the first 14 weeks of pregnancy. However, drugs other than zidovudine have not
been as thoroughly tested in pregnancy. The other
nucleoside analogues should be given during pregnancy only w h e n the benefits clearly outweigh the
risks. See Table 2.
Protease inhibitors..No major toxicities have been
o b s e r v e d as a result of taking either of the three
approved protease inhibitors. However, coadministration of ritonavir and non-sedating antihistamines, sedative hypnotics, or antiarrhythmics may produce life- threatening situations such as oversedation, respiratory an~t, or
cardiac arrest (see Table 4, Abramowicz, 1996; Olin, 1996).
Coadministration of these drugs with protease inhibitors
other than ritonavir has led to s'nnilar life- threatening reactions. Always identify all the drugs the client is taking
before prescribing or administering ritonavir.

Plan
During the planning phase, measurable goals are
mutually established between the client and the nurse. In
addition, the nurse makes a thorough assessment of all
the patient's drugs, including over-the-counter and
street drugs. In addition to the drug, route, dosage, and
frequency, the nurse must know whether the client is

JANAC Vol.7, No. 5, September-Octobe~1996

Table 4. Examples of Nonsedating Antihistamines, Sedative Hypnotics, and Antiarrhythmics*
Nonsedating Antihistamines

Sedative Hypnotics

Antiarrhythmics

Miscellaneous

Astemizole
Terfenadine

Alprazolam
Clorazepate
Diazepam
Estazolam
Flurazepam
Midazolam
Triazolam
Zolpidem

Amiodarone
Bepridil
Encainide
Flecainide
Propafenone
Quire'dine

Bupropion
Cisapfide
Clozapine
Meperidine
Piroxicam
Propoxyphene
Rifabufin

Adapted from Olin, B. (1996).Facts and comparisons. St. Louis: Lippincott.
* Not an indusive list

able to take the medication independently. If not, does
he or she have adequate social support to help with
taking the medications? Does the client have adequate
resources for obtaining the drug (i.e., money, insurance, transportation)? Since it is never enough to simply say, "Take y o u r medicine," nurses m u s t plan
methods for teaching the client about the medicines,
and must make themselves available to answer questions that arise after the client leaves the office. For
instance, the client may ask, "It is my birthday. Can I
have a glass of wine with my medications?" Nurses
can help the client find a w a y to procure the prescribed medications and to incorporate these medications into his or her life. Be familiar with industry,
social, or governmental compassionate drug programs
for indigent patients.
Implementation

Clients should be taught the name, dosage, route, and
frequency of any drug being prescribed. Apprise the
client of possible side effects and any special precautions
that must be taken while taking a particular drug.
Provide written instructions in addition to verbal ones.
Inform the client that current drugs are not a cure and
JANAC Vol.7, No. 5, September-Octobe~1996

will not prevent the transmission of HIV. Table 5 outlines
additional client instructions.
Ev~uation

Evaluation is an ongoing process and is performed at
every contact with the client. Assess for past or present
opportunistic infections or malignancies. A complete
blood count should be drawn at frequent intervals and
the results evaluated. If the client develops anemia or
granulocytopenia, a drug may need to be withdrawn,
the dosage changed, or another drug such as epoietin
alfa recombinant or granulocyte colony stimulating factor added. Liver, pancreatic, and renal values also should
be assessed at regular intervals.
Evaluation of antiretroviral therapy is based on viral
markers. Three viral markers have been more significant
than others in monitoring disease progression and treatment effectiveness: CD4+ cell counts, p24 antigenemia,
and viral load.
CD4+ cell counts. The normal CD4+ cell count ranges
from 589 to 1505 cells/~tl (Fischbach, 1996). T
helper/inducer cells (CD4+) are invaded and destroyed
by HIV. So a decline in CD4+ cells generally signifies disease progression (Flaskerud & Ungvarski, 1995) and
65
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Table 5. Client Instructions
Instruct client to:
Recognize and report the signs and symptoms of peripheral neuropathy fi.e., numbness, tingling, or pain in the
hands and feet).
2. Recognize and report the signs and symptoms of acute
pancreatitis (i.e., abdominal pain., nausea, or vomiting).
3. Recognize and report early signs and symptoms of anemia
(i.e., shortness of breath, increased weakness, tiredness,
fatigue, lightheadedness, dizziness, or palpitations).
4. Drink 2-3 liters of fluids per da3a
5. Report signs of opportunistic infections in the mouth (i.e.,
furry tongue, mouth lesion, or thrush), in the vagina (i.e.,
itching, burning, redness, or discharge), or in the rectum
(i.e, itching, drainage).
6. Avoid nonprescription medications unless approved by a
healthcare provider.
7. Takedrugs as scheduled to maintain an appropriate blood
level of the drug.
8. Avoid drug "holidays" (periods when the drug is not
taken), which may allow the development of resistant
strains of HIM
9. Takesaquinavir, ritonavir with food.
10. Take didanosine, indinavir, or zalcitabine on an empty
stomach.
11. Takestavudine, zidovudine, or lamivudine with or without food.
12. Chew, crush, or disperse didanosine in water before swallowing to release the buffer or to take it with a buffered
powder.
13. Understand that the long- term side effects of these drugs
remain unknown.
14. Takeprophylactic drugs to prevent opportunistic infections and malignancies.
15. Use contraceptives to prevent pregnancy while taking
antiretroviral drugs (remind the client that effective barrier
methods are needed to prevent the transmission of HW).
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indicates that the treatment strategy should be re- examined (Davey et al., 1996).
CD4+ cells can be destroyed by four processes: (1)
binding of gp120 can lead to preprogrammed cell death
k n o w n as apoptosis; (2) binding of gp120 can terminate
cell division known as anergy; (3) gp120 on the surface of
virions budding from the surface of an infected CD4+ cell
can bind to CD4+ receptors on other CD4+ cells, causing
them to tear; or (4) multiple CD4+ cells clump together in
a process known as syncytium formation, resulting in the
death of many CD4+ cells at one time (Peterson, 1995).
Antiretroviral treatment has been reserved for a CD4+
cell count less than 500 ceUg/n'lIn 3. Therapy should be initiated in clients who have a progressive dedine of CD4+ cells
to 500 cells/mm3 or in clients with a CD4+ cell count greater
than 500 cells/ram 3, if their CD4+ cells are rapidly declining
(Davey et al., 1996). Undoubtedl)4 new recommendations
be forthcoming regarding combination therapy.
The CD4+ cell count is an indirect m a r k e r of HIV
replication. Therefore, the cell count m a y rise in response
to an infection other than HIV or decline transiently in
response to stimuli other than increased viral replication
(Davey et al., 1996; Harrigan, 1995; Merigan, 1995). This
limits the significance of the CD4+ cell count in tracking
the progression of the disease or the effectiveness of therapy. In fact, it remains controversial w h e t h e r CD4+
counts have utility in predicting disease progression or
survival (Choi, Lagakos, Schoole)~ & Volberding, 1993).
However, in general, a significant reduction of the CD4+
cell count suggests that the treatment strategy needs to
be re-examined and that the treatment plan may need to
be changed (Davey et al., 1996).
p24 antigenemia. A n o t h e r test t h a t is u s e d as a
marker of disease progression is the p24 antigen test. The
p24 antigen is one of the core proteins. Early after infection antibodies to p24 appear. In the p24 antigen test, a
spectrophotometer is used to measure the optical density
that develops w h e n p24 antigen in a patient's serum
complexes with recombinant p24 antibody and is subjected to the e n z y m e linked anti-p24 ELISA test. The
greater the optical density, the greater the concentration
of p24 antigen in the patient's serum. Antibody forma-
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tion is one of the major problems associated with this
reliability of this test. In vivo, the HIV-infected person
makes antibodies to p24 in his or her serum. These antibodies attach to the p24 in the serum. In v/tro, the recombinant antibodies are unable to attach to the p24 antigen
unless the serum is treated with an acid wash. This acid
wash procedure releases the attachment of the p24 antigen- antibody complex, but it decreases the reliability of
this test. Therefore, its usefulness as a marker of disease
progression is limited (Piliero & Libman, 1996).
The p24 antigen test provides diagnostic information
in infants born to HIV-infected mothers. In the early
months after delivery, maternal antibodies to HIV and
other maternal antibodies persist in the infant. The infant
with antibodies to HIV may or may not be HIV- infected.
The presence of p24 antigen in the serum of the n e w
born allows early diagnosis and treatment of HIV infection (Cooper & Pelton, 1996).
Viral load. Viral load is a significant step in treating
HIV infection. HVA RNA levels have greater power to
predict disease progression than CD4+ cell count alone
(O'Brien et al., 1996). Since viral load is a direct marker of
viral replication, it does not rise and fall in relationship to
the white blood cell count. However, HIV viral load can
transiently increase in the presence of illnesses such as
pneumonia or influenza (Sax & Flory, 1996). Viral load
measures the presence of viral RNA in the plasma, but
not in other tissues (Davey et al., 1996).
Four methods are currently used to measure viral
load: (1) quantitative competitive polymerase chain reaction [PCR], (2) nucleic acid sequence-based amplification
[NASBA], (3) branched- chain DNA [b-DNA], and (4)
the amplicor microwell plate assay (Harrigan, 1995).
In the early, asymptomatic stage of HIV infection, viral
load may be about 5,000 virions/ml (Merigan, 1995). It rises
as the disease progresses and declines in response to effective anfiretroviral therapy (Davey et al., 1996). In advanced
stages of HIV infection, viral load may be as much as I million virions/ml (Merigan). A rise in viral load indicates
increased viral replication. A reduction in viral load greater
than 0.5 log10following initiation of treatment indicates that
the antiretroviral therapy is effective (Davey et al., 1996). If a
JANAC
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dienYs viral load fails to drop or does not drop by 0.5 log10
following treatment, the approach should be re-evaluated,
and the care plan may need to be modified (Davey et al.,
1996). Viral load determinations are recommended at baseline, prior to beginning antiretroviral therapj6 and approximately one month after beginning or changing antiretroviral therapy (Sax & Flory, 1996). Table 6 summarizes the
interpretation of HIV viral load testing.

Special Considerations
Clients should be advised to avoid "drug holidays"
(periods of time when drugs are not taken). Drug holidays permit activation of viral replication and increase
the risk of mutation and the development of resistant
strains. Resistance to one protease inhibitor may be conferred on other protease inhibitors and thus limit future
treatment options.
Avoid coadministration of nonsedating antihistamines,
sedative hypnotics, or anfiarrhythmics. When these drugs
are administered with the protease inhibitors, life threatening or lethal complications may arise (Olin, 1996). Examples
of each of the nonsedating antihistamines, sedative hypnotics, and antiarrhythmics are provided in Table 4.
Avoid coadministration of antiretroviral drugs with
similar adverse effects (Merigan, 1995). For instance,
a v o i d s i m u l t a n e o u s u s e of d i d a n o s i n e [ddI] and
dideoxycytidine [ddC], because acute pancreatitis and
peripheral neuropathy are adverse reactions of both
drugs (Davey et al., 1996; Merigan).
Nurses approach every aspect of patient care holistically, including the prescription and administration of
medications. Quite often, nurses work more closely with
the client than other clinicians. The nurse's responsibility
goes far beyond prescription and administration of a
medication. Nurses help people find resources to procure medications, teach them the effects and side effects
of their medications, teach them how to take their medication to obtain maximum benefit, and help them find
ways to incorporate drug therapies into their lives. When
an informed decision is made by the client to discontinue
antiretroviral therapy, the nurse supports the client.
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Table 6. Interpretation of H1V RNA V'tral Load

Viral Load

Clinical Significance of Results

< 10,000 copies per mm 3
10,000 to 100,000 copies per mm 3
> 100,000 copies per m m 3

Low risk of disease progression
Moderate risk of disease progression
High risk of disease progression

Adapted from Sax, P., & Flory, J. (1996). Information for patients: Viral load testing. AIDS Clinical Care, 8, p. 31
Discussion

Protease inhibitors and triple therapy provide a
n e w level of h o p e in the search for an effective treatm e n t for H I V infection ( W l o d a w e r & Erickson, 1993).
H o w e v e r , the a d v e n t of H I V p r o t e a s e i n h i b i t o r s presents n e w r e s e a r c h q u e s t i o n s . W h i c h c o m b i n a t i o n of
d r u g s is best for a particular g r o u p of clients? At w h a t
p o i n t s h o u l d a client be started o n a particular combin a t i o n of d r u g s ?
A l t h o u g h s l o w e r t h a n that of z i d o v u d i n e , d e v e l o p m e n t of resistance to H I V protease inhibitors has b e e n
noted (Markowitz et al., 1995; Martin et al., 1995; T~sdale
et al., 1995). This resistance reminds us that the search for
definitive prevention a n d treatment m u s t continue. The
progress m a d e with triple t h e r a p y is v e r y encouraging.
Strategies for treating H I V infection are rapidly increasing. Nurses, especially a d v a n c e d practice nurses providing care for HIV-infected individuals, m u s t keep current
w i t h n e w m e d i c a t i o n s that are b e i n g released. Existing
drugs, new drugs, combinations of those drugs, and
direct m e a s u r e m e n t of R N A viral load will allow individualization of treatment strategies.
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